Earnings Call · Q1 FY2023·2023-05-15

Q1 23EPS -6.67%·Rev n/aQ4 22EPS -100.00%*·Rev n/aQ3 22EPS +7.14%·Rev n/aQ2 22EPS +28.57%·Rev n/a⚠ consensus missing

PDS Biotechnology Corp PDSB

Gabrielle DeGravina — Investor Relations

Frank Bedu-Addo — Chief Executive Officer

Matt Hill — Chief Financial Officer

+7.4%1d on move date+7.1% vs SPY3d+9.5%5d+14.9%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more PDSB calls or request research access.

More PDSB calls Browse calls Request research access